H.R. 6142 would direct the Secretary of Health and Human Services (HHS) to develop a plan to reduce drug waste related to unused medicine in single-use packaging. Developing the plan would involve soliciting input from relevant stakeholders, including drug manufacturers, patient representatives, and health care providers. The Secretary would be required to issue a report to the Congress no later than 18 months after enactment of H.R. 6142. That report would include the plan as well as legislative options to reduce drug waste and manage drug costs.
Based on spending for similar activities, CBO estimates that implementing H.R. 6142 would cost about $1 million, assuming the availability of appropriated funds. Enacting H.R. 6142 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.
CBO estimates that enacting H.R. 6142 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2029.
H.R. 6142 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.